Remdesivir Shows Significant Survival Benefit Among Patients Hospitalized For SARS-CoV-2, Review Finds

Infectious Disease Advisor (5/23, Basilio) reported a systematic review and meta-analysis found that “clinical trial data and real-world evidence suggest remdesivir significantly improves survival and reduces rehospitalization risk among inpatients with SARS-CoV-2 across all disease severity levels.” Researchers analyzed a total of 122 unique studies “of randomized controlled trials (RCTs) and real-world studies published from January 2019 through December 2023 to summarize the effectiveness of remdesivir among inpatients with COVID-19.” The analysis “showed a significant overall survival benefit among inpatients with COVID-19 who received remdesivir, highlighting the need to ensure COVID-19 treatment recommendations remain aligned with evolving evidence.” The review was published in Clinical Infectious Diseases.